Ovarian Epithelial Tumor

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
EMA (1) FDA (2) HSE (2) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA1 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) HSE (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
EMA (1) FDA (1) FOLR1 positive Ovarian Epithelial Tumor Mirvetuximab soravtansine